Biomedical Innovations

 
Calgary, Alberta
Canada

Alim Mitha

Rahim Nathu

The FB Stent - Fluid Biotech

An aneurysm is a balloon off a blood vessel in the brain that could potentially bleed, resulting in devastating consequences for the patient. Brain aneurysms are common, and are present in up to 7% of the general population. Traditional treatment of complex brain aneurysms involves placing a metal “flow-diverting” stent across the neck of the aneurysm, leading to redirection of blood flow away from the aneurysm dome. Bioabsorbable flow-diverting stents have recently been developed by Fluid Biotech Inc. as a novel way to treat brain aneurysms.

Casey Smith

John Wong

Calgary, Alberta
Canada

SmartDrain

The device facilitates chest tube placement, combining depth control and ability to detect entry into the body cavity during insertion. The sharp central tip facilitates penetration of the chest wall. The device resembles a screw and advances into the chest through clockwise rotation, providing precise depth control. The tip also contains an electrical impedance manometer to alert when the pleural space has been breached. On entering the desired cavity, the central piece is removed from the screw-like body which remains on the chest wall. The device thus forms a conduit between the chest cavity and exterior for chest tube insertion.

Wiley Chung

 
Geneva
Switzerland

Olivier Preynat-Seauve

Nicolo Brembilla

Cellular Sponge for Treating Chronic Wounds

Chronic wounds, whose etiology includes diabetes and vascular diseases, affect more than 1% of the worldwide population. They strongly affect the quality of life of patients, causing chronic pain and a high risk of amputation. About 20% of patients fails the first-line therapy and enter a low-efficacy long-term vicious therapeutic cycle. This subgroup of patients eats up the majority of the wound-dedicated healthcare budget, equivalent to 1-3% of the total healthcare expenditure in developed countries. The medical need relies in the development of therapies able to effectively manage this patient subgroup while reducing the associated-costs.

We propose a solution based on the use of the own cells of the patient to treat. It relies in the application of an engineered autologous skin-like bilayer tissue composed by (i) an adipose-derived stem cell layer locally concentrating healing factors covered by (ii) a complete epidermal layer. This product, called Trophigraft, will be the first personalized, regenerative, single-application therapy reducing pain and allowing a wound to heal faster thanks to stem cells. We aim to position Trophigraft as second-line treatment. Thanks to simplicity of treatment and expected superior efficacy, Trophigraft may well represent an economically attractive solution for so far high-costly under-treated patients.

Geneva
Switzerland

Topical anti-VEGF Biologics Therapy for Wet AMD and Other Neovascular Diseases of the Eye

Intravitreal injections bear significant risks for the patient, including loss of eyesight upon microbiological contamination, inconvenience of regular intraocular injections are healthcare costs given the need to administer these drugs in hospital settings under aseptic conditions. About 38% of patients discontinue the therapy in just a period of 3 months. The conversion of the injectable therapy to a topical ocular therapy (eye drops), using the established concepts and active pharmaceutical ingredients such as Lucentis, would allow patient self-administration, increase compliance and contribute to significant healthcare care savings.

We have developed a platform technology that could improve the bioavailability of topical ophthalmic drugs from the current 5% to about 50%. Currently, about 80% of global eye diseases are being treated with eye drops. We developed a mechanism-driven, target selective drug penetration enhancement technology that can remove the barrier safely, therewith-increasing drug concentration in the target tissue of any eye drops from less than 5% to 50% efficacy. Being able to replace current intra-vitreal injection with eye drops represents a game changer for AMD treatment, a tremendous improvement of patient compliance, and a severe relief on health care costs. 

Sakthikumar Ragupathy

Gerrit Borchard

 
Hong Kong
China

Joanne Yip

Flexible Scoliosis Brace with Artificial Hinge

The innovative flexible brace is a functional garment specially designed for adolescent with scoliosis. The artificial hinge used in this design applies strategic corrective forces to the spine, providing adequate support to the wearers. Combining clinical practice, material science and textile technology, the scoliosis brace of high wearing comfort can control the progression of spinal deformity more effectively and improve patient compliance, thus reducing the possible need for surgery.

Special Features:

  • A multi-disciplinary collaborative project that involves experts in clinical practice, materials science, as well as textile and garment technology

  • The artificial hinge provides adequate support while allowing the wearer to retain certain mobility

  • Made of soft materials for enhanced patient compliance

  • Light weight with less heat and moisture build-up

  • Can be worn as a comfortable undergarment

Hong Kong
China

Enhanced Insulin Release by Ultrasound Stimulation for the Treatment of Diabetics

Lei Sun

 
Luxembourg City
Luxembourg

RADLAB.AI A Cloud-Based Sandbox to Unlock the Use and Evaluation of AI Algorithms in Radiology

Jean-Baptiste Niedercorn

Laetitia Huiart

Damien Drietrich

 
Toronto, Ontario
Canada

The “Liver Airbag” a new device for bleeding control in severe liver injuries.

For approximately 100 years, no new surgical device has been developed to specifically control bleeding from liver injuries, despite 80% mortality rate. This is the most frequent injury in abdominal trauma. More than 90,000 cases yearly in the U.S. alone. Weekly, we operate on two liver injuries at St. Michael’s Hospital. Severe liver injuries shatter the liver resulting in massive bleeding. Packing the shattered pieces is required to stop the bleeding. Currently, liver packing is done with gauze's with several limitations. They block direct view of the liver and create excessive pressure cutting the circulation to the organ. Gauze's also bond to the blood clots causing re-bleeding during removal. The “Liver Airbag” is the first and only device specifically developed to solve those problems. It is an inflatable-transparent device with two pressure gauges for precise control of the pressure applied to the liver, and does not bond to blood clots.

Joao Rezende-Neto